178 related articles for article (PubMed ID: 33245226)
1. C-C motif chemokine ligand 5 and C-C chemokine receptor type 5: possible diagnostic application in breast cancer patients.
Dąbrowska E; Przylipiak A; Zajkowska M; Piskór BM; Borowik-Zaręba A; Ławicki S
Acta Biochim Pol; 2020 Nov; 67(4):539-449. PubMed ID: 33245226
[TBL] [Abstract][Full Text] [Related]
2. The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer.
Üçüncü M; Serilmez M; Sarı M; Bademler S; Karabulut S
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31505877
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
[TBL] [Abstract][Full Text] [Related]
4. Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients.
Lubowicka E; Przylipiak A; Zajkowska M; Piskór BM; Malinowski P; Fiedorowicz W; Ławicki S
Biomed Res Int; 2018; 2018():2124390. PubMed ID: 30151375
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Biomarkers; 2017 Mar; 22(2):157-164. PubMed ID: 27775427
[TBL] [Abstract][Full Text] [Related]
6. CCL5 protein level: influence on breast cancer staging and lymph nodes commitment.
Derossi DR; Amarante MK; Guembarovski RL; de Oliveira CEC; Suzuki KM; Watanabe MAE; de Syllos Cólus IM
Mol Biol Rep; 2019 Dec; 46(6):6165-6170. PubMed ID: 31691056
[TBL] [Abstract][Full Text] [Related]
7. Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?
Zajkowska M; Gacuta E; Lubowicka E; Szmitkowski M; Ławicki S
Acta Biochim Pol; 2020 Mar; 67(1):25-29. PubMed ID: 32160452
[TBL] [Abstract][Full Text] [Related]
8. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
9. Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?
Attallah AM; El-Far M; Omran MM; Abdallah SO; El-Desouky MA; El-Dosoky I; Abdelrazek MA; Attallah AA; Elweresh MA; Abdel Hameed GE; Shawki HA; Salama KS; El-Waseef AM
Tumour Biol; 2014 Nov; 35(11):10737-45. PubMed ID: 25073515
[TBL] [Abstract][Full Text] [Related]
10. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of CCL5 -403 G>A and CCR5 Δ32 gene polymorphisms in patients with breast cancer.
Eskandari-Nasab E; Hashemi M; Ebrahimi M; Amininia S; Bahari G; Mashhadi MA; Taheri M
Cancer Biomark; 2014; 14(5):343-51. PubMed ID: 25171476
[TBL] [Abstract][Full Text] [Related]
12. Expression and biological functions of the CCL5-CCR5 axis in oral lichen planus.
Shan J; Li S; Wang C; Liu L; Wang X; Zhu D; Fan Y; Xu J
Exp Dermatol; 2019 Jul; 28(7):816-821. PubMed ID: 31006151
[TBL] [Abstract][Full Text] [Related]
13. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.
Lin S; Wan S; Sun L; Hu J; Fang D; Zhao R; Yuan S; Zhang L
Cancer Sci; 2012 May; 103(5):904-12. PubMed ID: 22380870
[TBL] [Abstract][Full Text] [Related]
14. The potential to target CCL5/CCR5 in breast cancer.
Velasco-Velázquez M; Xolalpa W; Pestell RG
Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
[TBL] [Abstract][Full Text] [Related]
15. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression.
Zhang Y; Yao F; Yao X; Yi C; Tan C; Wei L; Sun S
Oncol Rep; 2009 Apr; 21(4):1113-21. PubMed ID: 19288016
[TBL] [Abstract][Full Text] [Related]
16. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Ning Y; Cremolini C; Antoniotti C; Borelli B; Mashima T; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Lonardi S; Yamaguchi T; Falcone A; Loupakis F; Lenz HJ
Clin Colorectal Cancer; 2018 Jun; 17(2):e395-e414. PubMed ID: 29606345
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
19. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
[TBL] [Abstract][Full Text] [Related]
20. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
